Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 06:59 AM
October 2025
In this session, Emily Przybyl, PA-C from Erie County Medical Center in Buffalo, NY, explores current pharmacologic strategies for managing metabolic dysfunction–associated steatohepatitis (MASH) and metabolic dysfunction–associated steatotic liver disease (MASLD). She reviews the foundation of treatment—lifestyle modification, weight-loss interventions, and cardiovascular risk reduction—before detailing the evidence and clinical considerations for GLP-1 receptor agonists, vitamin E, pioglitazone, and the newly approved resmetirom. Emily discusses dosing strategies, histologic outcomes from major trials, and safety considerations including drug interactions, adverse effects, and monitoring recommendations. This presentation, part of the GHAPP MASLD & MASH Community Network and supported by Madrigal Pharmaceuticals, highlights how APPs can integrate emerging therapies into comprehensive, patient-centered management plans for MASLD and MASH.
Related Webcast
Webcast: MASLD Basics With Jessica Crimaldi
August 2025
Join Jessica Crimaldi, NP, from the Cleveland Clinic, for an in-depth and practical overview of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals. In this foundational session, Jessica breaks down the new 2023 steatotic liver disease nomenclature, replacing NAFLD and NASH with MASLD and MASH, and explains how these changes align with updated AASLD guidelines. Through a case-based approach, she walks through key diagnostic criteria, highlighting the role of cardiometabolic risk factors, non-invasive assessments such as FIB-4, FibroScan, and ELF, and when to consider liver biopsy for staging fibrosis. Learn how to stratify patients based on metabolic profiles, evaluate imaging and lab results, and identify those at risk for progression to advanced fibrosis or cirrhosis. Jessica also discusses global epidemiology, genetics (like PNPLA3), environmental contributors, and the clinical importance of early detection. With a comprehensive workup strategy for primary care and GI settings, this session equips providers to implement guideline-driven MASLD evaluation and referral practices for improved patient outcomes.
Watch Now
Webcast: Non-Invasive Testing With Sherona Bau
July 2025
In this engaging and highly informative GHAPP MASLD Community Network session, Sherona Bau, NP, walks attendees through a practical overview of non-invasive testing (NIT) for evaluating liver health in patients with MASLD (Metabolic dysfunction-associated steatotic liver disease) and MASH (Metabolic dysfunction-associated steatohepatitis). Drawing on real-world clinical experience, Sherona explains why non-invasive testing is essential for identifying fibrosis risk in a population where liver steatosis is prevalent in up to 30% of U.S. adults. Through the case of a 65-year-old Hispanic male named Albert, Sherona demonstrates how to interpret and apply tools such as FIB-4, FibroScan (VCTE and CAP score), ELF (Enhanced Liver Fibrosis) test, and MR Elastography (MRE). She highlights their respective strengths, limitations, clinical cut-offs, and insurance-related considerations. The session also covers when to order tests, how to assess data quality (e.g., IQR/median ratio in VCTE), and when to escalate care to hepatology or cardiology. Whether you are a primary care provider, endocrinologist, or hepatology specialist, this talk delivers practical algorithms and decision-making pathways for managing MASLD, improving early detection of fibrosis and cirrhosis, and integrating cardiovascular risk assessment into liver care. Sherona also emphasizes the importance of alcohol use history, metabolic syndrome risk factors, and annual NIT follow-up in patients at risk for disease progression.
Watch Now
Webcast: MASLD Basics With Anna Marie Hefner & Renee Pozza
October 2025
In this MASLD Community Network session, Anna Hefner, PhD, RN, CPNP, and Renee Pozza, PhD, RN, CNS, FNP-BC, of Southern California GI & Liver Centers break down the new nomenclature for steatotic liver disease (SLD) and what it means for clinical practice. They clarify how to distinguish MASLD from MASH, introduce the overlap category MetALD (metabolic-associated alcohol-related liver disease), and review differential causes of steatosis—from medications and viral hepatitis to genetic and cryptogenic etiologies. The faculty walk through practical primary-care screening with FIB-4, when to escalate with noninvasive tests (FibroScan® CAP/kPa, ELF), and the roles of ultrasound and MRI/MRE—plus when a liver biopsy is still warranted. You’ll learn staging cues (F0–F4), progression risk, who needs closer follow-up, and how to counsel patients on cardiometabolic risk reduction (weight loss, activity, triglyceride/HDL management, blood pressure, glucose). The talk also highlights pediatric considerations, terminology changes to reduce stigma, and tips for consistent waist-circumference measurement and alcohol-intake assessment—equipping PCPs, GI, and hepatology teams to identify fibrosis early and improve outcomes.
Watch Now
Webcast: MASLD Basics With Scott Springer
August 2025
Welcome to the GHAPP MASLD Community Network, where Scott Springer, PA-C, from Erie County Medical Center in Buffalo, NY, provides a comprehensive overview of the evolving landscape of steatotic liver disease. Sponsored by Madrigal Pharmaceuticals, this session breaks down the recent nomenclature shift from NAFLD/NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). Scott explores how overlapping etiologies like alcohol-associated liver disease (ALD) and the emerging classification of MetALD better reflect real-world patient populations. Learn about key diagnostic strategies—including the use of FIB-4, ELF score, and transient elastography—to assess fibrosis risk and guide referral to hepatology care. With a clinical case study, Scott highlights the importance of accurate staging, ruling out alternative etiologies, and understanding progression rates in high-risk patients. This session is a must-watch for GI and hepatology APPs looking to stay updated on guidelines, non-invasive diagnostics, and best practices for managing MASLD/MASH in primary and specialty settings.
Watch Now
Webcast: MASLD Basics With Emily Przybyl
September 2025
Emily Przybyl, PA-C, breaks down the basics of Steatotic Liver Disease (SLD) and the updated MASLD/MASH nomenclature—what changed, why it matters, and how to apply it in daily practice. You'll learn how to distinguish MASLD, MetALD, and alcohol-associated liver disease, interpret alcohol exposure (weekly vs. daily intake), and recognize non-metabolic causes of steatosis (DILI, monogenic disorders, viral hepatitis). Emily walks through primary care–friendly risk assessment using FIB-4, when to order VCTE/FibroScan or the ELF test, when to refer to hepatology, and when liver biopsy is still the right move in discordant cases. Using a real patient case, Emily demonstrates a stepwise chronic liver disease workup (viral serologies, iron studies, autoimmune markers, celiac, A1AT, HIV, lipids, A1C, and PEth for alcohol), plus how ultrasound findings (steatosis, smooth contour, spleen size) inform staging. She reviews natural history and progression (who’s at risk to advance to fibrosis/cirrhosis), the roles of genetics and the gut microbiome, and practical counseling on lifestyle modification—BMI/waist thresholds by ethnicity, cardiometabolic risk control, and culturally sensitive nutrition and exercise plans. Perfect for APPs, primary care, and hepatology teams looking for a clear, actionable primer on MASLD/MASH.
Watch Now
Webcast: MASLD Pharmacotherapy With Ann Moore
September 2025
Ann Moore, NP, Arizona Liver Health, delivers a practical overview of MASLD pharmacotherapy for the GHAPP MASLD Community Network, sponsored by Madrigal Pharmaceuticals. She covers the treatment toolbox—from lifestyle foundations (Mediterranean-style nutrition, sustainable weight loss, physical activity) and obesity/diabetes therapies (GLP-1 and GLP-1/GIP agents, bariatric surgery) to liver-directed options like vitamin E (in select non-diabetic patients), pioglitazone (for type 2 diabetes), and the THR-β agonist resmetirom for adults with non-cirrhotic MASH and F2–F3 fibrosis. You’ll learn when to stage with non-invasive tests (FibroScan®, ELF, MRI-PDFF), how to pair systemic and liver-targeted therapies, key safety and drug–drug considerations, and practical monitoring tips to keep patients on track. Ideal for APPs and GI/hepatology clinicians seeking an up-to-date, patient-centered roadmap to slow fibrosis and improve liver outcomes.
Watch Now
Webcast: MASLD Basics With Punam Punja
October 2025
Punam Punja, PA provides an overview of MASLD basics, explaining the 2023 terminology update that replaced NAFLD/NASH with MASLD/MASH and introduced MetALD for patients with metabolic dysfunction and alcohol exposure. Learn how to diagnose MASLD using imaging, metabolic risk factors, and non-invasive tests such as FIB-4, ELF, and FibroScan—plus when to refer for hepatology evaluation or liver biopsy. Punja also reviews staging, HCC surveillance, and practical lifestyle recommendations for patients at risk of fibrosis and cirrhosis.
Watch Now
Webcast: MASLD Pharmacotherapy With Elizabeth Alqueza
August 2025
In this presentation, Elizabeth Alqueza, PA-C at Beth Israel Deaconess Medical Center, provides a comprehensive overview of pharmacotherapy for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MASH. She highlights the latest treatment strategies, including lifestyle modifications, cardiovascular risk reduction, and targeted liver-directed therapies. Elizabeth reviews the role of GLP-1 receptor agonists in weight loss and liver health, the evidence for Vitamin E and Pioglitazone in select patients, and the landmark approval of Resmetirom (Rezdiffra)—the first FDA-approved therapy for MASH with moderate to advanced fibrosis. Drawing from clinical trial data, including the MAESTRO-NASH trial, she explains mechanisms of action, efficacy outcomes, safety considerations, and practical prescribing guidance. This session underscores the importance of combining non-invasive testing, lifestyle interventions, and emerging pharmacologic therapies to improve patient outcomes and prevent progression to cirrhosis and liver-related complications.
Watch Now
Webcast: MASLD Pharmacotherapy With HoChong Gilles
September 2025
In this MASLD Community Network webcast, HoChong Gilles, DNP from the Central Virginia VA Health Care System, provides an in-depth review of pharmacotherapy for MASLD and MASH. The session highlights how management historically focused on lifestyle modification, weight loss, and cardiometabolic risk reduction, and how the treatment landscape shifted in March 2024 with the FDA approval of resmetirom (Rezdiffra)—the first therapy specifically indicated for non-cirrhotic MASH with stage 2–3 fibrosis. HoChong also reviews the evidence and practical use of GLP-1 receptor agonists like semaglutide, including data from the ESSENCE trial, as well as the limited but notable roles of vitamin E and pioglitazone. Key discussion points include drug mechanisms, clinical trial outcomes, real-world safety considerations, drug–drug interactions, and monitoring strategies for patients on therapy. This presentation underscores the importance of integrating lifestyle change with emerging pharmacologic options to improve liver outcomes in patients with MASLD and MASH.
Watch Now
Webcast: MASLD vs MetALD With Jill Olmstead
November 2025
In this educational session, Jill Olmstead, DNP, from Providence Health in Southern California, reviews the new clinical guidelines for metabolic-associated steatotic liver disease (MASLD) and the emerging category MetALD—metabolic-associated liver disease related to alcohol use disorder. Through a case-based discussion, she explains how to evaluate patients with fatty liver disease, interpret key biomarkers like FIB-4 and FibroScan, and distinguish between metabolic and alcohol-related liver damage. Jill highlights the importance of weight loss, lifestyle modification, and alcohol cessation as essential interventions to reverse steatosis and fibrosis, and discusses the role of Resmetirom (Rezdiffra) as a newly approved therapy for patients with moderate to advanced fibrosis. This comprehensive overview helps clinicians and advanced practice providers apply updated MASLD and MetALD guidelines in everyday gastroenterology and hepatology practice.
Watch Now